Clinical Trial Results:
A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of maximal metformin therapy in patients with type 2 diabetes mellitus and insufficient glycemic control
Summary
|
|
EudraCT number |
2009-013549-27 |
Trial protocol |
BE NL FR IT ES |
Global completion date |
28 Sep 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
05 Apr 2015
|
Other versions |
|
Summary report(s) |
1218.62 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.